Evidence map›Paper›PMID 36865281›Full record

ArticlebioRxiv : the preprint server for biology2023

Multiplex Base Editing to Protect from CD33-Directed Therapy: Implications for Immune and Gene Therapy.

Florence Borot, Olivier Humbert, Gregory A Newby, Emily Fields, Sajeev Kohli, Stefan Radtke, George S Laszlo, Thiyagaraj Mayuranathan, Abdullah Mahmood Ali, Mitchell J Weiss and 5 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Florence Borot
Olivier Humbert
Gregory A Newby
Emily Fields
Sajeev Kohli
Stefan Radtke
George S Laszlo
Thiyagaraj Mayuranathan
Abdullah Mahmood Ali
Mitchell J Weiss
Jonathan S Yen
Roland B Walter
David R Liu
Siddhartha Mukherjee
Hans-Peter KiemORCID 0000-0001-5949-4947
Fred Hutch Cancer Center · USBroad Institute · USSt. Jude Children's Research Hospital · USColumbia University Irving Medical Center · USUniversity of Washington · USColumbia University · US

Funding

Novel Gene Editing Approaches for HemoglobinopathiesR01HL136135 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HANS-PETER KIEM · 2017 to 2026
$7.7M
In Vivo Hematopoietic Stem Cell Gene Therapy of Beta-Thalassemia and Sickle Cell DiseaseR01HL130040 · NHLBI · UNIVERSITY OF WASHINGTON · PI LIEBER, ANDRE MICHAEL · 2016 to 2024
$4.3M
Base-Edited Hematopoietic Stem and Progenitor Cells To Enable Safe Use Of Highly Potent CD33-Targeted RadioimmunotherapyR01CA266556 · NCI · FRED HUTCHINSON CANCER CENTER · PI Roland Bruno Walter · 2022 to 2026
$3.5M
NCI NIH HHS R01 CA266556NHLBI NIH HHS R01 HL130040NHLBI NIH HHS R01 HL136135
6 · The paper itself

Abstract

On-target toxicity to normal cells is a major safety concern with targeted immune and gene therapies. Here, we developed a base editing (BE) approach exploiting a naturally occurring CD33 single nucleotide polymorphism leading to removal of full-length CD33 surface expression on edited cells. CD33 editing in human and nonhuman primate (NHP) hematopoietic stem and progenitor cells (HSPCs) protects from CD33-targeted therapeutics without affecting normal hematopoiesis Graphical abstract:

Identifiers

PMID36865281
PMCPMC9980058
OpenAlexW4321604702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.